目的 探讨大蒜素肠溶胶囊联合莫西沙星治疗社区获得性肺炎的临床疗效。方法 纳入2022年7月—2025年3月首都医科大学附属北京友谊医院收治的社区获得性肺炎患者96例，按随机数字表法分为对照组和治疗组，每组各48例。对照组静脉滴注盐酸莫西沙星氯化钠注射液，0.4 g/次，1次/d。治疗组在对照组用药基础上餐后30 min口服大蒜素肠溶胶囊，40 mg/次，3次/d。两组患者疗程10 d。观察两组患者临床疗效，比较治疗前后两组患者症状缓解时间，肺炎严重指数（PSI）评分、胸部CT改良的CURB-65评分和睡眠障碍评定量表（SDRS）评分，及系统免疫炎症指数（SII）、全身炎症反应指数（SIRI）和血清C反应蛋白（CRP）、降钙素原（PCT）水平。结果 治疗后，治疗组总有效率为95.83%，明显高于对照组（83.33%，P＜0.05）。治疗后，与对照组相比，治疗组症状（咯痰、咳嗽、发热、肺部啰音）缓解时间均明显缩短（P＜0.05）。治疗后，两组PSI、胸部CT改良的CURB-65和SDRS评分均明显降低（P＜0.05），且治疗组评分比对照组更低（P＜0.05）。治疗后，两组SII、SIRI和血清CRP、PCT水平均显著下降（P＜0.05），且治疗组这些指标显著低于对照组（P＜0.05）。结论 大蒜素肠溶胶囊联合莫西沙星治疗社区获得性肺炎，能进一步增强抗感染效果，抑制机体炎症，加速患者的症状缓解，促进睡眠情况及病情和预后改善。

Objective To investigate the clinical efficacy of Alltride Enteric-coated Capsules combined with moxifloxacin in treatment of community acquired pneumonia. Methods Patients (96 cases) with community acquired pneumonia in Beijing Friendship Hospital, Capital Medical University from July 2022 to March 2025 were divided into control and treatment group according to random number table method, and each group had 48 cases. Patients in control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection, 0.4 g/time, once daily. Patients in treatment group were po administered with Alltride Enteric-coated Capsules 30 min after meals on the basis of the control group, 40 mg/time, three times daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluations were evaluated, and the symptom relief time, the scores of PSI, CURB-65 and SDRS, the SII, SIRI and PCT levels in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 95.83%, which was significantly higher than that in the control group (83.33%, P < 0.05). After treatment, compared with the control group, the relief time of symptoms (expectoration, coughing, fever, and rales in the lungs) in the treatment group was significantly shortened (P < 0.05). After treatment, the PSI, chest CT modified CURB-65 and SDRS scores were significantly reduced in two groups (P < 0.05), and the scores in the treatment group were lower significant than those in the control group (P < 0.05). After treatment, the levels of SII, SIRI, and serum CRP and PCT were significantly decreased in two groups (P < 0.05), and these indicators in the treatment group were lower significant than those in the control group (P < 0.05). Conclusion Alltride Enteric-coated Capsules combined with moxifloxacin in treatment of community-acquired pneumonia can further enhance the anti-infection effect, inhibit inflammation, accelerate the remission of patients′ symptoms, and promote the improvement of sleep condition, condition and prognosis.

R974